Pfizers efforts to secure exclusive rights to emerging GLP-1 modalities, including an oral GLP-1 candidate in early-stage development with Shanghai Fosuns YaoPharma, reflected a broader industry push to diversify delivery formats and expand market reach
Currently a number of research groups are developing histamine H 3 receptor antagonists as potential antiobesity agents
Compared to larger peptides, which often struggle with poor bioavailability and proteolytic degradation, tripeptides offer a balance of functional stability and conformational flexibility
Researchers have now learned there's an added bonus that may improve the prognosis for diabetics suffering from PAD, which is blocked arteries in mainly the legs
Advances and applications of nanoparticles in cancer therapy
Recently, it has been revealed that reactive oxygen species (ROS) produced excessively in the cells are involved in the process of skin aging caused by UV exposure